Obalon Therapeutics, Inc. (OBLN) Forms $4.13 Double Bottom; Palo Alto Investors Decreased Exact Sciences (EXAS) Stake

Exact Sciences Corporation (NASDAQ:EXAS) Logo

Palo Alto Investors Llc decreased Exact Sciences Corp (EXAS) stake by 28.22% reported in 2017Q4 SEC filing. Palo Alto Investors Llc sold 122,200 shares as Exact Sciences Corp (EXAS)’s stock declined 19.82%. The Palo Alto Investors Llc holds 310,876 shares with $16.33 million value, down from 433,076 last quarter. Exact Sciences Corp now has $6.03 billion valuation. The stock decreased 0.32% or $0.16 during the last trading session, reaching $49.86. About 1.39M shares traded. Exact Sciences Corporation (NASDAQ:EXAS) has risen 81.43% since May 3, 2017 and is uptrending. It has outperformed by 69.88% the S&P500.

Obalon Therapeutics, Inc. (OBLN) formed double bottom with $3.84 target or 7.00% below today’s $4.13 share price. Obalon Therapeutics, Inc. (OBLN) has $72.54 million valuation. The stock increased 1.98% or $0.08 during the last trading session, reaching $4.13. About 38,510 shares traded. Obalon Therapeutics, Inc. (NASDAQ:OBLN) has 0.00% since May 3, 2017 and is . It has underperformed by 11.55% the S&P500.

Among 18 analysts covering EXACT Sciences (NASDAQ:EXAS), 11 have Buy rating, 1 Sell and 6 Hold. Therefore 61% are positive. EXACT Sciences has $67.0 highest and $4 lowest target. $43.18’s average target is -13.40% below currents $49.86 stock price. EXACT Sciences had 75 analyst reports since July 24, 2015 according to SRatingsIntel. As per Wednesday, May 31, the company rating was maintained by Canaccord Genuity. The firm has “Buy” rating by Leerink Swann given on Thursday, August 24. The firm earned “Buy” rating on Friday, April 27 by Canaccord Genuity. The firm has “Buy” rating by BTIG Research given on Tuesday, April 3. The stock of Exact Sciences Corporation (NASDAQ:EXAS) has “Neutral” rating given on Monday, November 13 by Robert W. Baird. The stock has “Neutral” rating by Goldman Sachs on Tuesday, October 6. The stock of Exact Sciences Corporation (NASDAQ:EXAS) earned “Hold” rating by Benchmark on Wednesday, October 26. The firm has “Neutral” rating by Goldman Sachs given on Monday, August 15. As per Wednesday, May 31, the company rating was maintained by Roth Capital. Canaccord Genuity maintained it with “Buy” rating and $55.0 target in Friday, February 23 report.

Palo Alto Investors Llc increased Wright Med Group N V stake by 59,900 shares to 2.74 million valued at $60.75M in 2017Q4. It also upped Sage Therapeutics Inc (NASDAQ:SAGE) stake by 23,555 shares and now owns 810,806 shares. Immunomedics Inc (NASDAQ:IMMU) was raised too.

Since January 2, 2018, it had 0 buys, and 20 selling transactions for $24.73 million activity. 12,352 Exact Sciences Corporation (NASDAQ:EXAS) shares with value of $522,959 were sold by ARORA MANEESH. $756,271 worth of Exact Sciences Corporation (NASDAQ:EXAS) was sold by LIDGARD GRAHAM PETER. Conroy Kevin T had sold 101,488 shares worth $4.64 million on Friday, February 9. The insider Doyle James Edward sold 3,098 shares worth $126,925. Carey Thomas D. sold 8,448 shares worth $335,630. COWARD D SCOTT also sold $141,341 worth of Exact Sciences Corporation (NASDAQ:EXAS) on Friday, March 9. On Friday, February 23 the insider Elliott Jeffrey Thomas sold $126,252.

Investors sentiment decreased to 0.88 in 2017 Q4. Its down 0.13, from 1.01 in 2017Q3. It dived, as 25 investors sold EXAS shares while 105 reduced holdings. 44 funds opened positions while 70 raised stakes. 92.48 million shares or 1.24% less from 93.65 million shares in 2017Q3 were reported. Alps Advsrs has 0% invested in Exact Sciences Corporation (NASDAQ:EXAS) for 3,998 shares. Piedmont Inv Ltd reported 4,695 shares. Lombard Odier Asset Mgmt (Usa) reported 86,731 shares or 0.35% of all its holdings. Mutual Of America Capital Llc holds 0.08% or 105,954 shares in its portfolio. Dupont Cap Management Corp accumulated 22,279 shares. 5,668 are owned by Zeke Advisors Ltd Co. Gotham Asset Ltd Llc holds 0.16% in Exact Sciences Corporation (NASDAQ:EXAS) or 215,037 shares. Horseman Cap Management Ltd owns 0.3% invested in Exact Sciences Corporation (NASDAQ:EXAS) for 27,000 shares. Rmb Capital Lc owns 13,665 shares. Thompson Inv Management Incorporated, Wisconsin-based fund reported 225,830 shares. Alpha Windward Limited Company owns 0.01% invested in Exact Sciences Corporation (NASDAQ:EXAS) for 289 shares. Axa holds 0.03% or 131,500 shares in its portfolio. Jpmorgan Chase And Company invested in 0.03% or 2.72M shares. 222,818 were reported by Tiverton Asset Management Ltd Liability. Retail Bank Of New York Mellon Corporation owns 0.01% invested in Exact Sciences Corporation (NASDAQ:EXAS) for 624,560 shares.

Among 2 analysts covering Obalon Therapeutics (NASDAQ:OBLN), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Obalon Therapeutics has $21 highest and $18 lowest target. $19.50’s average target is 372.15% above currents $4.13 stock price. Obalon Therapeutics had 2 analyst reports since October 31, 2016 according to SRatingsIntel. The firm has “Buy” rating by Stifel Nicolaus given on Monday, October 31. UBS initiated the stock with “Buy” rating in Monday, October 31 report.

Analysts await Obalon Therapeutics, Inc. (NASDAQ:OBLN) to report earnings on May, 9. They expect $-0.54 earnings per share, down 14.89% or $0.07 from last year’s $-0.47 per share. After $-0.60 actual earnings per share reported by Obalon Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -10.00% EPS growth.

Exact Sciences Corporation (NASDAQ:EXAS) Institutional Positions Chart